Evidence map›Paper›PMID 38320549›Full record

ArticleCell2024

A synthetic differentiation circuit in Escherichia coli for suppressing mutant takeover.

David S Glass, Anat Bren, Elizabeth Vaisbourd, Avi Mayo, Uri Alon

Open access · hybridAbstract read
In one paragraph

Article in Cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

David S GlassDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel. Electronic address: david.glass@weizmann.ac.il.
Anat BrenDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel.
Elizabeth VaisbourdDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel.
Avi MayoDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel.
Uri AlonDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel. Electronic address: uri.alon@weizmann.ac.il.
Weizmann Institute of Science · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Differentiation is crucial for multicellularity. However, it is inherently susceptible to mutant cells that fail to differentiate. These mutants outcompete normal cells by excessive self-renewal. It remains unclear what mechanisms can resist such mutant expansion. Here, we demonstrate a solution by engineering a synthetic differentiation circuit in Escherichia coli that selects against these mutants via a biphasic fitness strategy. The circuit provides tunable production of synthetic analogs of stem, progenitor, and differentiated cells. It resists mutations by coupling differentiation to the production of an essential enzyme, thereby disadvantaging non-differentiating mutants. The circuit selected for and maintained a positive differentiation rate in long-term evolution. Surprisingly, this rate remained constant across vast changes in growth conditions. We found that transit-amplifying cells (fast-growing progenitors) underlie this environmental robustness. Our results provide insight into the stability of differentiation and demonstrate a powerful method for engineering evolutionarily stable multicellular consortia.

Indexed as

Escherichia coliSynthetic BiologyCell DifferentiationDrug Resistance, BacterialGenetic FitnessIntegrasesIntegrasesdifferentiationfitness landscape engineeringmulticellular consortiaprogenitorsrobustnessstem cell nichestem cellssynthetic biologysynthetic developmentsynthetic multicellularitytransit-amplifying cells

Identifiers

PMID38320549
PMCPMC10882425
OpenAlexW4391542031

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.